GRAL · GRAIL Inc. Common Stock
View on chartInsiders & Stakes
| ILLUMINA, INC. | ▼ Sell | Open Market | 3,502,126 Shares held | 11/17/2025 | View profile |
| DING CHUN R | ▼ Sell | Open Market | 3,305,055 Shares held | 7/1/2025 | View profile |
| Robert P. Ragusa Chief Executive Officer | ▼ Sell | Open Market | 518,582 Shares held | 4/8/2026 | View profile |
| Joshua J. Ofman Chief Executive Officer | ▼ Sell | Open Market | 362,271 Shares held | 9/21/2026 | View profile |
| Aaron Freidin Chief Financial Officer | ▼ Sell | Open Market | 225,364 Shares held | 10/5/2026 | View profile |
| Andrew John Partridge Chief Growth Officer | ▼ Sell | Open Market | 155,865 Shares held | 10/5/2026 | View profile |
| Gregory L. Summe Director | ▲ Buy | Grant | 45,672 Shares held | 7/15/2026 | View profile |
| William J. Chase Director | ▲ Buy | Grant | 42,978 Shares held | 7/15/2026 | View profile |
| Steven Mizell Director | ▲ Buy | Grant | 42,830 Shares held | 7/15/2026 | View profile |
| Sarah Krevans Director | ▲ Buy | Grant | 42,628 Shares held | 6/18/2026 | View profile |
Transaction History
| Andrew John Partridge | ▼ Sell | Open Market | 7,873 | $1.2M | 10/5/2026 |
| Aaron Freidin | ▼ Sell | Open Market | 23,619 | $3.5M | 10/5/2026 |
| Aaron Freidin | ▼ Sell | Open Market | 1,779 | $164K | 9/21/2026 |
| Aaron Freidin | ▼ Sell | Open Market | 1,800 | $169K | 9/21/2026 |
| Aaron Freidin | ▼ Sell | Open Market | 521 | $49K | 9/21/2026 |
| Joshua J. Ofman | ▲ Buy | Option Exercise | 26,452 | $370K | 9/21/2026 |
| Joshua J. Ofman | ▼ Sell | Open Market | 2,125 | $196K | 9/21/2026 |
| Joshua J. Ofman | ▼ Sell | Open Market | 1,454 | $136K | 9/21/2026 |
| Joshua J. Ofman | ▼ Sell | Open Market | 37,752 | $3.6M | 9/21/2026 |
| Joshua J. Ofman | ▼ Sell | Open Market | 6,200 | $598K | 9/21/2026 |
| Joshua J. Ofman | ▼ Sell | Open Market | 1,400 | $137K | 9/21/2026 |
| Joshua J. Ofman | ▼ Sell | Open Market | 421 | $42K | 9/21/2026 |
| Joshua J. Ofman | ▼ Sell | Open Market | 2,100 | $211K | 9/21/2026 |
| Joshua J. Ofman | ▼ Sell | Open Market | 10,000 | $1.1M | 9/21/2026 |
| Joshua J. Ofman | ▼ Sell | Open Market | 5,000 | $425K | 8/27/2026 |
| Aaron Freidin | ▼ Sell | Open Market | 7,900 | $672K | 8/27/2026 |
| William J. Chase | ▲ Buy | Grant | 276 | $21K | 7/15/2026 |
| Gregory L. Summe | ▲ Buy | Grant | 427 | $32K | 7/15/2026 |
| Steven Mizell | ▲ Buy | Grant | 268 | $20K | 7/15/2026 |
| William J. Chase | ▲ Buy | Grant | 5,491 | $350K | 6/18/2026 |
| Steven Mizell | ▲ Buy | Grant | 5,491 | $350K | 6/18/2026 |
| Gregory L. Summe | ▲ Buy | Grant | 5,491 | $350K | 6/18/2026 |
| Sarah Krevans | ▲ Buy | Grant | 5,491 | $350K | 6/18/2026 |
| Andrew John Partridge | ▼ Sell | Open Market | 1,491 | $91K | 6/4/2026 |
| Joshua J. Ofman | ▲ Buy | Grant | 3,154 | $193K | 6/3/2026 |
| Joshua J. Ofman | ▲ Buy | Grant | 27,901 | $1.8M | 6/1/2026 |
| Steven Mizell | ▲ Buy | Grant | 396 | $20K | 4/15/2026 |
| William J. Chase | ▲ Buy | Grant | 408 | $20K | 4/15/2026 |
| Gregory L. Summe | ▲ Buy | Grant | 631 | $31K | 4/15/2026 |
| Aaron Freidin | ▼ Sell | Open Market | 45,806 | $2.3M | 4/8/2026 |
| Robert P. Ragusa | ▼ Sell | Open Market | 123,502 | $6.2M | 4/8/2026 |
| Joshua J. Ofman | ▼ Sell | Open Market | 61,665 | $3.1M | 4/8/2026 |
| Aaron Freidin | ▼ Sell | Open Market | 2,407 | $115K | 3/9/2026 |
| Aaron Freidin | ▼ Sell | Open Market | 85 | $4K | 3/9/2026 |
| Joshua J. Ofman | ▼ Sell | Open Market | 2,836 | $136K | 3/9/2026 |
| Joshua J. Ofman | ▼ Sell | Open Market | 101 | $5K | 3/9/2026 |
| Robert P. Ragusa | ▼ Sell | Open Market | 7,203 | $345K | 3/9/2026 |
| Robert P. Ragusa | ▼ Sell | Open Market | 258 | $12K | 3/9/2026 |
| Aaron Freidin | ▼ Sell | Open Market | 655 | $35K | 3/5/2026 |
| Joshua J. Ofman | ▼ Sell | Open Market | 690 | $37K | 3/5/2026 |
| Robert P. Ragusa | ▼ Sell | Open Market | 980 | $52K | 3/5/2026 |
| Joshua J. Ofman | ▼ Sell | Open Market | 779 | $40K | 3/2/2026 |
| Joshua J. Ofman | ▼ Sell | Open Market | 16,223 | $813K | 3/2/2026 |
| Aaron Freidin | ▼ Sell | Open Market | 9,135 | $458K | 3/2/2026 |
| Aaron Freidin | ▼ Sell | Open Market | 438 | $23K | 3/2/2026 |
| Robert P. Ragusa | ▼ Sell | Open Market | 35,787 | $1.8M | 3/2/2026 |
| Robert P. Ragusa | ▼ Sell | Open Market | 1,717 | $89K | 3/2/2026 |
| Joshua J. Ofman | ▲ Buy | Grant | 84,540 | $4.5M | 2/27/2026 |
| Aaron Freidin | ▲ Buy | Grant | 60,118 | $3.2M | 2/27/2026 |
| William J. Chase | ▲ Buy | Grant | 213 | $21K | 1/15/2026 |
| Gregory L. Summe | ▲ Buy | Grant | 329 | $32K | 1/15/2026 |
| Steven Mizell | ▲ Buy | Grant | 206 | $20K | 1/15/2026 |
| Joshua J. Ofman | ▼ Sell | Open Market | 13,000 | $1.3M | 12/3/2025 |
| Robert P. Ragusa | ▼ Sell | Open Market | 14,807 | $1.4M | 12/3/2025 |
| Robert P. Ragusa | ▼ Sell | Open Market | 15,356 | $1.5M | 12/3/2025 |
| Robert P. Ragusa | ▼ Sell | Open Market | 8,233 | $792K | 12/3/2025 |
| Robert P. Ragusa | ▼ Sell | Open Market | 1,604 | $156K | 12/3/2025 |
| Aaron Freidin | ▼ Sell | Open Market | 25,000 | $2.5M | 12/3/2025 |
| Aaron Freidin | ▼ Sell | Open Market | 1,697 | $134K | 11/17/2025 |
| ILLUMINA, INC. | ▼ Sell | Open Market | 1,000,000 | $79.8M | 11/17/2025 |
| Joshua J. Ofman | ▼ Sell | Open Market | 6,114 | $501K | 10/16/2025 |
| Robert P. Ragusa | ▼ Sell | Open Market | 7,239 | $499K | 10/15/2025 |
| Steven Mizell | ▲ Buy | Grant | 267 | $20K | 10/15/2025 |
| Joshua J. Ofman | ▼ Sell | Open Market | 8,865 | $674K | 10/15/2025 |
| Gregory L. Summe | ▲ Buy | Grant | 425 | $32K | 10/15/2025 |
| William J. Chase | ▲ Buy | Grant | 275 | $21K | 10/15/2025 |
| Joshua J. Ofman | ▼ Sell | Open Market | 81,385 | $5.1M | 10/6/2025 |
| Joshua J. Ofman | ▼ Sell | Open Market | 9,692 | $620K | 10/2/2025 |
| Joshua J. Ofman | ▼ Sell | Open Market | 4,202 | $135K | 8/19/2025 |
| Aaron Freidin | ▼ Sell | Open Market | 877 | $28K | 8/19/2025 |
| William J. Chase | ▲ Buy | Grant | 533 | $21K | 7/15/2025 |
| Gregory L. Summe | ▲ Buy | Grant | 825 | $32K | 7/15/2025 |
| Aaron Freidin | ▼ Sell | Open Market | 8,000 | $311K | 7/15/2025 |
| Steven Mizell | ▲ Buy | Grant | 517 | $20K | 7/15/2025 |
| DING CHUN R | ▼ Sell | Open Market | 51,125 | $2.5M | 7/1/2025 |
| DING CHUN R | ▼ Sell | Open Market | 260,832 | $12.9M | 7/1/2025 |
| DING CHUN R | ▼ Sell | Open Market | 27,843 | $1.4M | 7/1/2025 |
| Joshua J. Ofman | ▼ Sell | Open Market | 9,692 | $504K | 6/30/2025 |
| Joshua J. Ofman | ▼ Sell | Open Market | 9,692 | $410K | 6/12/2025 |
| Gregory L. Summe | ▲ Buy | Grant | 6,082 | $250K | 5/29/2025 |
| William J. Chase | ▲ Buy | Grant | 6,082 | $250K | 5/29/2025 |
| Steven Mizell | ▲ Buy | Grant | 6,082 | $250K | 5/29/2025 |
| Sarah Krevans | ▲ Buy | Grant | 6,082 | $250K | 5/29/2025 |
| Joshua J. Ofman | ▼ Sell | Open Market | 48,213 | $1.6M | 5/2/2025 |
| Aaron Freidin | ▼ Sell | Open Market | 41,150 | $1.4M | 5/2/2025 |
| Robert P. Ragusa | ▼ Sell | Open Market | 94,035 | $3.2M | 5/2/2025 |
| William J. Chase | ▲ Buy | Grant | 784 | $20K | 4/15/2025 |
| Steven Mizell | ▲ Buy | Grant | 760 | $20K | 4/15/2025 |
| Gregory L. Summe | ▲ Buy | Grant | 1,212 | $31K | 4/15/2025 |
| Robert P. Ragusa | ▼ Sell | Open Market | 7,625 | $238K | 3/7/2025 |
| Joshua J. Ofman | ▼ Sell | Open Market | 2,109 | $66K | 3/7/2025 |
| Aaron Freidin | ▼ Sell | Open Market | 1,816 | $57K | 3/7/2025 |
| Joshua J. Ofman | ▼ Sell | Open Market | 525 | $22K | 3/5/2025 |
| Robert P. Ragusa | ▼ Sell | Open Market | 994 | $41K | 3/5/2025 |
| Aaron Freidin | ▼ Sell | Open Market | 521 | $22K | 3/5/2025 |
| Joshua J. Ofman | ▲ Buy | Grant | 110,770 | $3.2M | 2/3/2025 |
| Robert P. Ragusa | ▲ Buy | Grant | 224,620 | $6.5M | 2/3/2025 |
| Aaron Freidin | ▲ Buy | Grant | 69,230 | $2.0M | 2/3/2025 |
| William J. Chase | ▲ Buy | Grant | 1,182 | $21K | 1/15/2025 |
| Gregory L. Summe | ▲ Buy | Grant | 1,828 | $32K | 1/15/2025 |
| Steven Mizell | ▲ Buy | Grant | 1,147 | $20K | 1/15/2025 |
| Aaron Freidin | ▼ Sell | Open Market | 30,452 | $427K | 11/18/2024 |
| William J. Chase | ▲ Buy | Grant | 210 | $3K | 10/30/2024 |
| Steven Mizell | ▲ Buy | Grant | 248 | $3K | 10/30/2024 |
| Gregory L. Summe | ▲ Buy | Grant | 296 | $4K | 10/30/2024 |
| Sarah Krevans | ▲ Buy | Grant | 31,055 | $0 | 10/21/2024 |
| Steven Mizell | ▲ Buy | Grant | 978 | $14K | 10/15/2024 |
| Gregory L. Summe | ▲ Buy | Grant | 1,656 | $23K | 10/15/2024 |
| Robert P. Ragusa | ▼ Sell | Open Market | 123,454 | $1.7M | 10/15/2024 |
| William J. Chase | ▲ Buy | Grant | 1,054 | $15K | 10/15/2024 |
| DING CHUN R | ▲ Buy | Open Market | 16,200 | $209K | 10/9/2024 |
| Aaron Freidin | ▲ Buy | Grant | 45,840 | $576K | 10/3/2024 |
| DING CHUN R | ▲ Buy | Open Market | 35,000 | $445K | 10/3/2024 |
| Joshua J. Ofman | ▲ Buy | Grant | 106,970 | $1.3M | 10/3/2024 |
| Joshua J. Ofman | ▲ Buy | Grant | 152,810 | $1.9M | 10/3/2024 |
| Aaron Freidin | ▲ Buy | Grant | 79,460 | $999K | 10/3/2024 |
| DING CHUN R | ▼ Sell | Other | 70,000 | $880K | 10/3/2024 |
| Robert P. Ragusa | ▲ Buy | Grant | 214,240 | $2.7M | 10/3/2024 |
| Robert P. Ragusa | ▲ Buy | Grant | 45,840 | $576K | 10/3/2024 |
| DING CHUN R | ▲ Buy | Open Market | 20,000 | $267K | 10/2/2024 |
| DING CHUN R | ▲ Buy | Open Market | 7,629 | $103K | 10/1/2024 |
| Joshua J. Ofman | ▼ Sell | Open Market | 74,084 | $1.2M | 8/21/2024 |
| Aaron Freidin | ▼ Sell | Open Market | 15,641 | $254K | 8/21/2024 |
| Aaron Freidin | ▲ Buy | Grant | 187,636 | $0 | 6/28/2024 |
| Joshua J. Ofman | ▲ Buy | Grant | 257,912 | $0 | 6/28/2024 |
| Robert P. Ragusa | ▲ Buy | Grant | 475,178 | $0 | 6/28/2024 |
| Gregory L. Summe | ▲ Buy | Grant | 26,470 | $0 | 6/25/2024 |
| Steven Mizell | ▲ Buy | Grant | 26,470 | $0 | 6/25/2024 |
| William J. Chase | ▲ Buy | Grant | 26,470 | $0 | 6/25/2024 |
| ILLUMINA, INC. | ▼ Sell | Other | 26,547,021 | $0 | 6/24/2024 |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 11, 2026
Grail hits 12-month high after FDA panel win
Grail stock reached a 12-month high following a favorable FDA panel decision. This event has driven significant price movement, with the stock up 171% over the last six months. While some analysts view the current valuation as high, others see potential for continued growth. The company is also preparing to present new data from major clinical trials at upcoming medical conferences.
Grail hits 12-month high after FDA panel win. Grail stock reached a 12-month high following a favorable FDA panel decision. This event has driven significant price movement, with the stock up 171% over the last six months. While some analysts view the current valuation as high, others see potential for continued growth. The company is also preparing to present new data from major clinical trials at upcoming medical conferences.